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Abstract
Background: Omalizumab (Xolair®), a recombinant monoclonal anti-IgE antibody, has demonstrated efficacy in
clinical trials conducted in patients with moderate to severe persistent allergic asthma. We aimed to investigate the
efficacy, discontinuation and medical resource utilization of omalizumab in the real-life setting in Taiwan.
Methods: This study was a retrospective, population-based database cohort study using the Taiwan NHIRD from
2007 to 2011 assessing the efficacy of omalizumab therapy over 4 months on changes in asthma medication, asthma
control, frequency of exacerbations and hospitalization rates at baseline and after omalizumab discontinuation.
Results: There was a reduction in asthma medication post omalizumab therapy and severe exacerbations and
hospitalizations from baseline (31.2 %, n = 282) to the end of follow-up (11.8 %, n = 144, p < 0.001). Nearly all the
patients received chronic oral corticosteroids at baseline (92.4 %). The number of ER visits decreased from 1.13 ± 2.04 to
0.29 ± 0.83, and the mean number of admissions decreased from 5.93 ± 16.16 to 2.75 ± 12.02 from baseline to the
end of follow-up (p < 0.001). After discontinuation of omalizumab, the cost of ER medical expenses decreased from
New Taiwan dollars (NTD) 3934 at 2 months to NTD 2860 at 12 months.
Conclusions: Patients who received omalizumab therapy for over 4 months were more likely to reduce the use of
other asthma medications and less likely to experience an asthma exacerbation, ER visits, and hospitalization, even after
the discontinuation of omalizumab. These data suggest that omalizumab has efficacy in improving health outcomes in
patients with moderate to severe predominately chronic oral steroid dependent asthma in the real-life setting in Taiwan.
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Background
Asthma is a chronic inflammatory disease of the airways,
and the symptoms can usually be relieved with inhaled
corticosteroids (ICS) [1]. The majority of patients with
asthma suffer from mild-to-moderate disease which may
be relatively well controlled with the use of standard
therapy. However, in 5 ~ 10 % of asthma patients the
symptoms may continue to progress even with high-
dose inhaled and oral corticosteroid treatment [2].
Patients with difficult-to-treat asthma may require repeated
hospital admissions thereby incurring increased healthcare
costs and affecting their working performance [3].
Evidence indicates that 50 % to 80 % of difficult-to-
treat patients have an allergic component, with IgE
playing a key role in triggering and maintaining allergic
airway inflammation [4–8]. Omalizumab (Xolair®), a
recombinant monoclonal anti-IgE antibody, has demon-
strated efficacy in clinical trials conducted in patients
with moderate to severe and severe persistent allergic
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(IgE-mediated) asthma in reducing the risk of exacerba-
tions, hospitalization, and emergency room (ER) visits
[4, 8]. Omalizumab was licensed in Taiwan in 2008 for
patients aged 6 years and older with severe persistent
allergic asthma that was inadequately controlled despite
the use of high-dose ICS plus long-acting β2 agonists
(LABA). Numerous randomized clinical trials have shown
that adding omalizumab to current asthma therapy is ef-
fective and well tolerated [9–12]. Data from these clinical
studies have shown that add-on therapy with omalizumab
significantly reduces asthma exacerbations, use of ICS and
ER/hospital visits. The results from a large cohort of
patients with severe uncontrolled asthma showed that
add-on omalizumab was associated with a significantly
decreased risk of hospitalization or ER visits in patients
with uncontrolled severe asthma in real-life practice [13].
Recently, a 2-year, international, post-marketing observa-
tion registry (eXpeRience) [14] was conducted to evaluate
the real-world effectiveness, safety and use of omalizumab
therapy in 943 patients with uncontrolled persistent
allergic asthma. The results confirmed the effectiveness of
omalizumab in improving asthma control, the number
and severity of exacerbations, symptoms, lung function
and healthcare utilization, both in a real-world setting and
in a clinically controlled study setting.
The objective of this retrospective cohort study was to
compare the effectiveness and benefits of long-term
(>4 months) omalizumab treatment and those after
discontinuation of treatment in real-life medical practice.
Reductions in asthma exacerbations and utilization of
asthma-related medical resources in Taiwanese patients
with uncontrolled persistent allergic asthma were assessed
using a population-based claims database.
Methods
Study design
This was a retrospective, database cohort study using
the Taiwan National Health Insurance Research Data-
base (NHIRD) from 2007 to 2011.
Data sources
The NHIRD contains comprehensive claims records of
outpatient and inpatient care of enrollees in the National
Health Insurance (NHI) program in Taiwan, which
covers over 99 % of the population in Taiwan (more than
23 million people). This health claims database includes
health care data and medical utilization details as well as
basic information from all hospitals contracted with the
NHI program, and is updated annually. Each individual
is assigned a unique identity number (hence longitudinal
data are available), and the available information in-
cludes basic demographics, details of medical services,
detailed information on prescribed medications, diagno-
ses from specialists’ referrals and hospital admissions.
The NHI Bureau has established a uniform system to
control the quality of medical services and coding. The
identification data of the beneficiaries in the NHIRD is
scrambled to protect their privacy before they are released
for research purposes. NHIRD was not freely available and
Chang Gung Memorial Hospital (CGMH) and Novartis,
Taiwan granted access to it. This study was supported by
CGMH and Novartis, Taiwan [Grant XMRPG 3C1071]
and was exempted from full review by the Institutional
Review Board of CGMH (102-3778B).
Sample size justification
Since this is a retrospective, descriptive study in which no
formal statistical testing was performed, the use of point
estimates and 95 % confidence intervals (CIs) served to
quantify the level of precision. There were 46, 130, 156,
196 patients prescribed with omalizumab, respectively,
based on which year they received it in the NHIRD claims
database, allowing to quantify the patterns of omalizumab
usage and other anti-asthmatic regimen in routine prac-
tice with sufficient precision (frequency, proportions and
95 % CIs were calculated).
Patient population
Patients with allergic asthma (International Classification of
Diseases, 9th Revision, Clinical Modification [ICD-9-CM]
codes 493.0, 493.9, 493.1 and 493.8) were identified from
the dataset. The source population consisted of all sub-
jects who had at least one prescription for omalizumab as
part of an anti-asthma regimen between January 1, 2008
and December 31, 2011. The index date was defined as
the time of first prescription of omalizumab. Data were
collected from 1 year before the initiation of omalizumab
treatment to 4 years after treatment initiation or until the
end of 2011, whichever came first. The patients who
discontinued omalizumab remained in the database
and were followed up until the end of the observation
period. We were only evaluating patients who receive
omalizumab > 4 months. We aimed to investigate the
efficacy, discontinuation and medical resource utilization
of omalizumab in the real-life setting in Taiwan. In
addition, we evaluated the reduction in asthma medication
post omalizumab therapy and severe exacerbations and
hospitalizations from baseline to the end of follow-up lon-
gitudinally. Thus, we did not enroll a matched cohort not
receiving omalizumab who are equally severe.
Variables (outcomes of interests)
Demographics and patient characteristics recorded from
the database included age at cohort entry, gender, asthma
disease history, and diagnosis. Past medical history,
previous asthma medication, co-morbidities, diagnosing/
prescribing doctor’s specialty and level of institution were
also recorded.
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Omalizumab use and treatment observation
Data on the treatment regimen including dose, duration,
prescription refill schedule/interval, change in dose and
discontinuation were recorded. Information on the co-
use of other asthma medication, previous medication,
co-medications, and their doses, and whether or not
they were used with omalizumab (ICS, LABA + ICS, oral
corticosteroids [OCS], short-acting muscarinic antagonist
[SAMA] and long-acting muscarinic antagonist [LAMA])
was also recorded. Data were collected at initiation, and
then 4, 6, 8, and 12 months before discontinuing omalizu-
mab, and 2, 6, and 12 months after discontinuing omalizu-
mab. Discontinuation of therapy was defined as a gap in
therapy of 56 days.
Treatment effectiveness
The number of asthma events, and asthma-related med-
ical resource utilization including hospitalization, ER visits
and medication use to manage acute exacerbations were
recorded. The time to recurrence (exacerbation event) or
worsening of asthma symptoms after discontinuing omali-
zumab treatment was also recorded. Other data including
the number of clinically significant asthma exacerbations
and severity of these exacerbations, and the use of OCS
and other asthma maintenance medications and the
reasons for discontinuing or changing omalizumab treat-
ment defined as asthma exacerbations were also recorded.
Severe exacerbation was defined as: ER visit or hospi-
talization >1 day with OCS >20 mg/day; Non-severe ex-
acerbation was defined as: OCS >20 mg/day without ER
visit or hospitalization.
Data analysis
All the analysis was conducted using SAS statistical soft-
ware, version 9.3 (SAS Institute Inc, Cary, NC). Exacer-
bations in baseline and follow-up period were expressed
as percentage and compared by using Fisher’s exact test.
Patient number and dosages, ER visit and hospitalization
of using other asthma medication post omalizumab ther-
apy were defined as continuous variables and were com-
pared by using Fisher’s exact test. Mean changes from
baseline for ER visits and hospitalizations post omali-
zumab therapy was expressed by frequency and using
paired-T test for comparison. Data were summarized
with respect to demographic and baseline characteristics,
effectiveness, and reasons for discontinuing omalizumab
treatment. Descriptive statistics were presented as num-
ber, mean, and standard deviation (SD) for continuous
variables, and frequency, percentage, and 95 % CI for
categorical variables.
In addition to the overall analysis, the evaluations were
stratified according to treatment persistence (duration).
The prescriptions, usage, co-medications, asthma-related
events, number of acute exacerbations, medical resource
utilization, and cost were analyzed and compared be-
tween different treatment persistence groups.
Results
Characteristics of the study subjects
Table 1 shows the characteristics of the study subjects.
In total, 46, 130, 156, and 196 patients received omalizu-
mab in 2008, 2009, 2010, and 2011, respectively, based
on which year they received it in the NHIRD claims
database,
The prescribing pattern and duration of omalizumab
treatment
In total, 282 patients (161 male, 57.1 %) who received
omalizumab had moderate to severe asthma with mean
age of 51.3 ± 17.2 years. Nearly all the patients received
chronic oral corticosteroids at baseline (92.4 %). The mean
duration of omalizumab treatment was 243.8 ± 265.4 days,
and 44 % of the patients received omalizumab for less
than 4 months with mean duration of 70.1 ± 34.8 days
(Fig. 1a). Of the remaining 56 % of the patients who
received omalizumab for more than 4 months, 15 %
received treatment for 4–6 months, 12 % for 6–8 months,
9 % for 8–12 months, and 21 % for more than 12 months
(Fig. 1b).
Decreases in other asthma medications post omalizumab
therapy
At the end of follow-up, there was a significant decrease
in the use of ICS, LABA/ICS, OCS, and SAMA (p < 0.001)
as well as LAMA post omalizumab (p < 0.05) (Table 2).
There was a reduction in all asthma medications com-
pared to baseline 2 months before the discontinuation of
omalizumab. The doses of LABA/ICS, OCS, and SAMA
also decreased post omalizumab therapy (p < 0.001)
(Table 3).
Table 1 Characteristics of the study subjects
2008 2009 2010 2011
Asthma
New asthma patients 791,730 434,854 376,048 385,942
All asthma patients 791,730 813,806 828,300 899,375
MOWH asthma patients 785,831 808,008 822,800 878,220
SAA
New SAA patients 46,982 30,828 29,632 28,195
All SAA patients 46,982 48,116 51,072 52,439
Omalizumab
New omalizumab patients 46 90 69 77
All omalizumab patients 46 130 156 196
MOHW Ministry of Health and Welfare, SAA severe allergic asthma
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Decreased number of severe exacerbations post
omalizumab therapy
There was a reduction in severe exacerbations or
hospitalizations from baseline: 1 year before index day
(31.2 %, n = 282) to follow-up: 2 months before discon-
tinuation (Discontinuation of therapy was defined as a
gap in therapy of 56 days.) (11.8 %, n = 144, p < 0.001).
The number of ER visits and hospitalizations post omali-
zumab therapy decreased from 43.7 to 17.1 % and 34.8 to
17.7 %, respectively (p < 0.001) (Table 4). The mean num-
ber of ER visits decreased from 1.13 ± 2.04 to 0.29 ± 0.83
and the mean number of admissions decreased from
5.93 ± 16.16 to 2.75 ± 12.02 over the study period from
baseline (1 year before the index date) to 2 months before
the discontinuation of omalizumab (p < 0.001) (Table 5).
Reductions in the dose of ICS + LABA, LABA and OCS,
exacerbations, ER visits and cost after the discontinuation
of omalizumab
With regards to changes in medication after the dis-
continuation of omalizumab for 12 months, there was
a 68 % ~77 % reduction in ICS + LABA, LABA and a
65 % ~ 72 % reduction in OCS compared with base-
line (Fig. 2a). The doses of ICS + LABA, LABA and OCS
after the discontinuation of omalizumab also decreased
(Fig. 2b). There was a 69.0 % ~87.5 % reduction in the
number of exacerbations (Fig. 3a) and a 29.4 % ~ 36.5 %
reduction in ER visits (Fig. 3b) after the discontinuation of
omalizumab compared with baseline. After the discon-
tinuation of omalizumab, the mean cost of ER medical
expenses decreased fro New Taiwan Dollar (NTD) 3934 at
2 months to NTD 2860 at 12 months.
Discussion
This study was a retrospective, population-based database
cohort study using the Taiwan NHIRD from 2007 to 2011.
The patients who received omalizumab therapy for over
4 months were more likely to have reductions in other
asthma medications and less likely to experience an
asthma exacerbation-related ER visit and hospitalization.
There were also reductions in the number of asthma
medications, exacerbations and ER visits after the discon-
tinuation of omalizumab at 2, 6, and 12 months compared







All 282 100.0% 243.8±265.4 51.3±17.2 161 (57.1%)
≤4 months (≤120 days) 124 44.0% 70.1±34.8 53.7±17.1 67 (54.0%)
4 ~6 months (120<days≤180 ) 42 14.9% 143.9±14.6 53.4±16.2 24 (57.1%)
6~8 months (180 < days≤240) 33 11.7% 211.7±21.4 49.3±15.1 21 (63.6%)
8~12months (240 < days≤360) 25 8.9% 290.3±33.7 50.1±15.7 15 (60.0%)

















≤4 months (≤120 days) 4 ~6 months  
(120<days≤180 ) 
6~8 months (180 < 
days≤240)
8~12months  (240 < 
days≤360)
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A
B
Fig. 1 The duration and prescribing pattern of omalizumab: a The duration of omalizumab treatment: A total of 282 patients with moderate to
severe asthma receiving omalizumab were enrolled. The mean duration of omalizumab treatment was 243.8 ± 265.4 days. b The prescribing
pattern: Overall, 44 % of the patients received omalizumab therapy for less than 4 months with a mean duration of 70.1 ± 34.8 days, and 56 % of
the patients received omalizumab for more that 4 months, including 15 % (4–6 months), 12 % (6–8 months), 9 % (8–12 months), and 21 %
(over 12 months)
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effective in improving health outcomes in patients with
moderate to severe asthma in routine clinical practice in
Taiwan. To the best of our knowledge, this is the first co-
hort study on this issue to use a national population-based
database.
Omalizumab has been shown to be effective in
double-blind placebo-controlled trials [15]. The reduc-
tion in the use of OCS observed in this study is in
agreement with observations in a previous study [16].
Omalizumab may therefore decrease the potential for
steroid-associated morbidities in patients with inad-
equately controlled severe allergic asthma. Molimard et al.
suggested that omalizumab given to patients treated in a
real-life setting provided a similar benefit to that observed
in clinical trials [17], suggesting that the efficacy demon-
strated in randomized controlled trials (RCTs) [8, 18–23]
can be transposed to a real-life setting. A more recent
study from Ireland [24] showed that the significant reduc-
tion in the number of exacerbations, hospitalizations and
weekly need for rescue treatment validated the clinical
benefits of omalizumab therapy in their population. The
reduction in ICS and OCS use reflects improved symptom
control, thereby facilitating stepping down from max-
imum standard therapy. A recent cohort study compared
clinical outcomes 52 weeks pre- and post-omalizumab
therapy, and the results showed that omalizumab treat-
ment resulted in improved asthma control, with a signifi-
cant reduction in asthma exacerbations and systemic
steroid courses required and improvements in asthma
control test (ACT) score [25]. The magnitude of the
improvement of omalizumab in real-life setting was com-
parable to that observed in RCTs.
A retrospective analysis representing a preliminary report
from the northeast of Italy reported that a moderate but
statistically significant improvement in forced-expiratory
volume in 1 s (FEV1), and an increasing proportion of ex-
acerbation-free patients were observed after the initiation
of treatment [26]. These findings were independent of the
baseline severity of bronchial obstruction. A positive im-
pact of omalizumab on rhinitis in patients with both
asthma and rhinitis was also detected. Observed reduc-
tions in asthma-related events in particularly poorly con-
trolled patients in an Italian [27] real-life setting are
consistent with the results of other observational studies
in France [17] and Germany [28]. In Israel, Rottem
showed that omalizumab as an add-on therapy reduced
the use of corticosteroids and improved the control of
asthma, as evidenced by a reduced number of asthma-
related ER visits [29]. Our study is compatible with the
findings from these studies in Western countries, and it is
the first study in Asia to use a nationwide database.
The mean duration of omalizumab treatment was
243.8 days in our study, however the optimal duration of
omalizumab immunotherapy for responders who have
Table 2 Changes in other asthma medications post
omalizumab therapy
Duration >120 days Baselinea Follow-upb p-valuec
N = 158 N (%) N (%)
ICS <0.001*
With ICS 158 (100.0 %) 138 (87.3 %)
Without ICS 0 (0.0 %) 20 (12.7 %)
ICS + LABA <0.001*
With ICS + LABA 157 (99.4 %) 124 (78.5 %)
Without ICS + LABA 1 (0.6 %) 34 (21.5 %)
OCS <0.001*
With OCS 146 (92.4 %) 91 (57.6 %)
Without OCS 12 (7.6 %) 67 (42.4 %)
SAMA <0.001*
With SAMA 49 (31.0 %) 4 (2.5 %)
Without SAMA 109 (69.0 %) 154 (97.5 %)
LAMA 0.027*
With LAMA 27 (17.1 %) 13 (8.2 %)
Without LAMA 131 (82.9 %) 145 (91.8 %)
aBaseline: 1 year before the index date
bFollow-up: 2 months before discontinuation (discontinuation of therapy was
defined as a gap in therapy of 56 days)
cFisher’s exact test, *P < 0.05
Table 3 Changes in LABA/ICS dosages, OCS, SAMA, and LAMA post omalizumab therapy
Duration >120 days Baselinea Follow-upb Change from baseline p-valuec
N = 158 Mean ± SD Mean ± SD Mean ± SD
ICS plus LABA
Dose of salmeterol and fluticasone (mcg/day) 302.73 ± 236.28 215.82 ± 243.06 −86.91 ± 198.03 <0.001*
Dose of formoterol and budesonide (mcq/day) 162.72 ± 157.55 102.95 ± 149.38 −59.76 ± 138.84 <0.001*
OCS(tab/day) 1.99 ± 1.27 1.17 ± 1.66 −0.81 ± 1.61 <0.001*
SAMA(bottle/month) 0.44 ± 0.88 0.03 ± 0.21 −0.41 ± 0.86 <0.001*
LAMA(bottle/month) 0.15 ± 0.36 0.13 ± 0.47 −0.01 ± 0.47 0.6935
aBaseline: 1 year before the index date
bFollow-up: 2 months before discontinuation (discontinuation of therapy was defined as a gap in therapy of 56 days)
cFisher’s exact test, *P < 0.05
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benefited remains undetermined. There are limited data
on asthma control after the cessation of omalizumab
therapy. In the current study, 21 % of the patients re-
ceived omalizumab therapy for over 12 months with a
mean duration of 685.8 days, and persistent benefits
were found after the discontinuation of omalizumab. In
our results, there were reductions in ICS + LABA and
OCS use in the patients who received over 4 months of
omalizumab therapy for 12 months compared with
baseline. There were also reductions in exacerbations
and ER visits after the discontinuation of omalizumab
for 12 months compared with baseline. Nopp et al.
reported that there was no rebound phenomenon in the
patients in whom omalizumab therapy was stopped after
being treated for 6 years, and the patients reported that
their asthma control continued to improve or remained
unchanged when compared with being on treatment.
Interestingly, the observed considerable down-regulation
of basophil allergen sensitivity, cluster of differentiation
(CD)-sens, which most likely represents mast cell
allergen sensitivity, has been reported to contribute to
clinical results [10]. Molimard et al. [30] published the
results of a retrospective observational study on severe
asthmatic patients after discontinuation of omalizumab
therapy. Twenty-four lung specialists reviewed data from
61 responding patients who had discontinued omalizumab
Table 5 Mean changes from baseline for ER visits and
hospitalizations post omalizumab therapy
Duration >120 days Baselinea Follow-upb Change from
baseline
p-valuec
N = 158 Mean ± SD Mean ± SD Mean ± SD
ER visit
(person × times/year) 1.13 ± 2.04 0.29 ± 0.83 −0.83 ± 2.05 <0.001*
Inpatient visit
(person × times/year) 5.93 ± 16.16 2.75 ± 12.02 −3.18 ± 13.03 <0.001*
aBaseline: 1 year before index day
bFollow-up: 2 months before discontinuation (discontinuation of therapy was
defined as a gap in therapy of 56 days)
cMean change from baseline by paired T test, *p < 0.05
Table 4 ER visits and hospitalizations post omalizumab therapy
Duration >120 days Baseline a Follow-up b p-valuec
N = 158 N (%) N (%)
ER visit <0.001*
Yes 69 (43.7 %) 27 (17.1 %)
No 89 (56.3 %) 131 (82.9 %)
Inpatient visit <0.001*
Yes 55 (34.8 %) 28 (17.7 %)
No 103 (65.2 %) 130 (82.3 %)
aBaseline: 1 year before the index date
bFollow-up: 2 months before discontinuation (discontinuation of therapy was
defined as a gap in therapy of 56 days)











































Fig. 2 a Follow-up changes of ICS + LABA and OCS after the
discontinuation of omalizumab (% change from baseline). Follow-up of
changes in medication after the discontinuation of omalizumab for
12 months. There was a 68 % ~77 % reduction in ICS + LABA and a
65 %~ 72 % reduction in OCS compared with baseline. Follow-up
period: time point ± 14 days after omalizumab discontinuation; Time
points: 2 months, 6 months, 12 months; Discontinuation of therapy
was defined as a gap in therapy of over 56 days. b Dose of ICS + LABA
and OCS after omalizumab discontinuation. The dose of ICS + LABA
and OCS decreased after the discontinuation of omalizumab.
Discontinuation of therapy was defined as a gap in therapy of
over 56 days
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after a mean duration of 22.7 months of treatment. A loss
of asthma control was documented in 34 patients (55.7 %)
with a median interval between discontinuation and loss
of control of 13.0 months. The discontinuation of omali-
zumab was not associated with any rebound effect or
exacerbation of the disease, and control was sustained
throughout the follow-up period of at least 6 months in
nearly half of all patients, including all of those who had
been treated for 3.5 years or more. After the reintro-
duction of omalizumab, 4 out of 20 patients did not
respond again. The INNOVATE study (INvestigation of
Omalizumab in seVere Asthma TrEatment) revealed that
omalizumab withdrawal after 28 weeks of therapy led to
the re-emergence of asthma symptoms, which correlated
well with increasing free IgE and decreasing concen-
trations of the drug in serum. Reducing the dose of
omalizumab below that in the dosing table was not
recommended, as the resulting increase in free IgE would
cause deterioration in asthma control [31]. However, a
more recent study indicated that the withdrawal of omali-
zumab therapy after successful long-term therapy may
cause severe asthma exacerbations [32]. In this study, for
patients with at least 4 months of omalizumab therapy,
there were reductions in asthma medications, exacerba-
tions and ER visits after the discontinuation of omalizu-
mab at 2, 6, and 12 months compared with baseline. A
longer follow-up period may be warranted in future







































Fig. 3 Changes in exacerbations and ER visits for the patients who experienced these events at baseline. a Exacerbation reduction: There was a
69.0 % ~87.5 % reduction in exacerbations after omalizumab discontinuation compared with baseline. b ER reduction: There was a 29.4 % ~
36.5 % reduction of ER visit after omalizumab discontinuation compared with baseline
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treatment should be undertaken individually after care-
fully weighing up the benefits and risks, especially in
patients with a long history of severe asthma, and in those
treated with high doses of OCS before omalizumab treat-
ment is initiated. The high percentage of patients on oral
steroids seems higher than other omalizumab for asthma
studies, indicating they are more severe and complicated.
Nearly all the patients received chronic oral corticoste-
roids at baseline (92.4 %). These data suggest that omali-
zumab has efficacy in improving health outcomes in
patients with moderate to severe predominately chronic
oral steroid dependent asthma in the real-life setting in
Taiwan.
There are limitations in this retrospective, population-
based database cohort study. A limitation of this study is
that there is a major bias introduced by selecting suc-
cessful patients who continued omalizumab for 4 months
or more after initiation, especially when the drug could
only be continued after 3 months in successful people.
There is significant selection bias by excluding patients
who did not complete at least 4 months of omalizumab.
In total, 282 patients who received omalizumab had
moderate to severe asthma. The mean duration of
omalizumab treatment was 243.8 days, and 44 % of the
patients received omalizumab for less than 4 months
with mean duration of 70.1 days. We excluded the
patients who did not complete 4 months of omalizumab
therapy because some of the patients who discontinued
omalizumab therapy had different confounding factors
even though they were responders. However, because
40 % of patients who were taking omalizumab for less
than 4 months, they may not have experienced a re-
sponse if they would have taken it for greater than
4 months. It was hard to distinguish these patients be-
cause this was a retrospective, population-based data-
base cohort study. In addition, as it costs much, NHI
Bureau strictly audited the duration of omalizumab use
every 3 months under controlled budget in Taiwan. 44 %
of patients received omalizumab less than 4 months and
79 % less than one year in this study. Those who re-
spond ascertain the value of continuous omalizumab
use, whereas non-responders are likely to have other
confounding factors such as poor adherence, persistent
allergen exposure or other obstructive airway diseases
[33]. Finally, we did not enroll a matched cohort not re-
ceiving omalizumab who are equally severe. The reasons
for not doing this include that we aimed to investigate
the efficacy, discontinuation and medical resource utili-
zation of omalizumab in the real-life setting in Taiwan
and evaluated the reduction in asthma medication post
omalizumab therapy and severe exacerbations and hos-
pitalizations from baseline to the end of follow-up longi-
tudinally. The impacts and limitations should also be
acknowledged including that the improvements in clinical
outcomes reported may be due to other factors than treat-
ment with omalizumab including regular asthma clinic re-
view and improved adherence with asthma therapies.
Conclusions
In summary, this study highlights patients who receive
omalizumab therapy for over 4 months are less likely to
experience an asthma exacerbation and hospitalization.
Even after the discontinuation of omalizumab, the re-
duction of asthma medication, exacerbation and hospi-
talization were also observed. They were also more likely
to require reduced maintenance oral and ICS therapy as
well as the need for rescue therapy. Nearly all the pa-
tients received chronic oral corticosteroids at baseline
(92.4 %). These population-based data suggest that oma-
lizumab may be effective in improving health outcomes
for patients with moderate and severe predominately
chronic oral steroid dependent asthma in the real-life
setting in Taiwan.
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